Speedy EU approval for AZ's key new anticancer Lynparza
This article was originally published in Scrip
AstraZeneca's first-in-class anticancer olaparaib has received its first worldwide approval in the EU as Lynparza for use in ovarian cancer, less than two months after it was given the go-ahead by the CHMP. The company told Scrip is was aiming to get Lynparza to market across the EU as quickly as possible and that the UK and some of the Nordic markets were likely to be among the first to launch it in 2015.
You may also be interested in...
Two late-stage trials of Austedo have missed their endpoints in the neurological disorder, meaning Teva will miss out on an additional revenue stream from the VMAT2 inhibitor.
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.
Insmed shares got a 40% boost as the company announced plans to move into Phase III this year with its potential first-in-class candidate for the lung disease.